Abstract:Abstract Background Canine parvovirus (CPV) emerged in 1970s as a new causative disease of dogs worldwide. The virus was shown to be closely related, genetically and antigenically, to feline parvovirus (FPV) and to FPV-like parvoviruses from which were presumably originated by host species shift and subsequent rapid adaptation. CPV is the most important viral cause of enteritis and death in puppies, and vaccination is the most important and effective measure to prevent CPV infection. The live attenuated vaccine strain NL-35-D is widely used as a commercial vaccine in China and other countries, but its genome sequence has not been reported so far. Results We reported a near full length sequence of NL-35-D vaccine strain (Genbank: MW650831), and identified a CPV-SH2001 (Genbank: MW650830) and a FPV-SH2001 (Genbank: MW650831) isolates from the fecal samples of stray dogs and cats in Shanghai, respectively. Immunofluorescence assay revealed that the CPV and FPV isolates could be proliferated by F81 cells. we sequenced the full length genome of NL-35-D virus strain, phylogenetic analysis of full-length genome and VP2 gene in comparison with the CPV and FPV strains isolated worldwide. According to the genetic analysis of VP2 gene, the CPV-SH2001 and FPV-SH2001 isolates were clustering far from the NL-35-D. However, the results demonstrated that NL-35-D vaccine strain still shares part of neutralizing epitopes with CPV and FPV isolates. The neutralizing antibody serum test also suggested vaccine strain NL-35-D is still effective against the present field isolated CPV and FPV strains. Therefore, these shared antigenic epitopes may be critical to the immune efficacy of the vaccine and deserve further testing and validation. Conclusions Our results revealed that pups inoculated with CPV vaccine had significantly high neutralizing antibody titers against CPV and FPV virus strains. Pups vaccinated with CPV possess antibodies against heterologous viruses, the antibodies probably at levels still can provide complete or partial immunity in young pups.

Genetic analysis of CPV vaccine strain NL-35-D and evaluation of induced neutralizing antibody against virulent wild-type CPV and FPV Shanghai isolates